Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Fruquintinib provides improvement in overall survival for refractory mCRC
Dr Nageshwara Arvind Dasari - MD Anderson Cancer Center, Houston, USA
Fruquintinib provides improvement in overall survival for refractory mCRC ( Dr Nageshwara Arvind Dasari - MD Anderson Cancer Center, Houston, USA )
12 Sep 2022
ESMO 2022: Breast cancer highlights
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
ESMO 2022: Breast cancer highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
12 Sep 2022
Sotorasib demonstrates superior PFS vs docetaxel for previously treated non-smal...
Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA
Sotorasib demonstrates superior PFS vs docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation ( Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA )
12 Sep 2022
Cabozantinib in combination w/ nivolumab and ipilimumab of IMDC intermediate or ...
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
Cabozantinib in combination w/ nivolumab and ipilimumab of IMDC intermediate or poor risk significantly improved PFS vs PBO ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
12 Sep 2022
Emerging systemic therapies in rare urothelial cancer variants
Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA
Emerging systemic therapies in rare urothelial cancer variants ( Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA )
12 Sep 2022
Lenvatinib plus pembro for aRCC - update on the CLEAR study
Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA
Lenvatinib plus pembro for aRCC - update on the CLEAR study ( Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA )
12 Sep 2022
Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim ...
Prof Matthew P Goetz - Mayo Clinic, Rochester, USA
Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim data ( Prof Matthew P Goetz - Mayo Clinic, Rochester, USA )
12 Sep 2022
Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast can...
Prof Matthew P Goetz - Mayo Clinic, Rochester, USA
Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast cancer: ELAINE trial ( Prof Matthew P Goetz - Mayo Clinic, Rochester, USA )
12 Sep 2022
Nivolumab and ipilimumab with tumour-infiltrating lymphocytes to treat triple-ne...
Dr Iris Nederlof - The Netherlands Cancer Institute, Amsterdam, Netherlands
Nivolumab and ipilimumab with tumour-infiltrating lymphocytes to treat triple-negative breast cancer ( Dr Iris Nederlof - The Netherlands Cancer Institute, Amsterdam, Netherlands )
12 Sep 2022
Atezolizumab improves on single-agent chemo for NSCLC not eligible for platinum-...
Prof Siow-Ming Lee - University College London, London, UK
Atezolizumab improves on single-agent chemo for NSCLC not eligible for platinum-containing regimen ( Prof Siow-Ming Lee - University College London, London, UK )
12 Sep 2022
Results from a phase 3 study of 1L atezolizumab vs single-agent chemotherapy in ...
Prof Siow-Ming Lee - University College London, London, UK
Results from a phase 3 study of 1L atezolizumab vs single-agent chemotherapy in pts with NSCLC ( Prof Siow-Ming Lee - University College London, London, UK )
12 Sep 2022
RADICALS-HD trial: androgen deprivation therapy with post-operative radiotherapy...
Prof Chris Parker - Institute of Cancer Research, Sutton, UK
RADICALS-HD trial: androgen deprivation therapy with post-operative radiotherapy to treat prostate cancer ( Prof Chris Parker - Institute of Cancer Research, Sutton, UK )
12 Sep 2022